Exxel Pharma's Innovative Small Molecule, EX937, Rapidly Advancing Toward First-In-Human Study for the Treatment of Refractory Chronic Cough
Refractory chronic cough represents a significant unmet need with no FDA-approved treatment options and $11B total ...
pulmonologyadvisor3d
Chronic Cough Reduced Through Behavioral Cough Suppression Therapy
Behavioral cough suppression therapy may be effective in patients with refractory and unexplained chronic cough (RCC and UCC).
Exxel Pharma to Participate in a “New to Virtual Investor” Segment
AURORA, CO / ACCESS Newswire / January 31, 2025 / Exxel Pharma ("Exxel" or the "Company"), a pharmaceutical company dedicated to developing novel therapeutics for the treatment of neuronal ...
Trevi Therapeutics To Participate In Upcoming February Investor Conferences
Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference February 11-12, 2025 Corporate Presentation: February 11, 9:20 - 9:50 am ET Trevi Representatives: Jennifer Good, President and CEO, ...
Sacramento Bee5d
Exxel Pharma’s Innovative Small Molecule, EX937, Rapidly Advancing Toward First-In-Human Study for the Treatment of Refractory Chronic Cough
Refractory chronic cough represents a significant unmet need with no FDA-approved treatment options and $11B total addressable global market First-in-human Phase 1/1b single/multiple dose study in ...
Kansas City Star8d
Exxel Pharma to Participate in a “New to Virtual Investor” Segment
Exxel is initiating a first-in-human Phase 1/1b clinical study of EX937 for refractory chronic cough, a significant unmet medical need with no FDA-approved treatments. In preclinical studies ...
Eagle-Tribune5d
Exxel Pharma's Innovative Small Molecule, EX937, Rapidly Advancing Toward First-In-Human Study for the Treatment of Refractory Chronic Cough
Refractory chronic cough represents a significant unmet need with no FDA-approved treatment options and $11B total addressable global market First-in-human Phase 1/1b single/multiple dose study in ...